Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

Also called NCT07844603

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07844603
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07844603. Randomized; no masking; primary purpose treatment. Start 2027-01-01 (anticipated); primary completion 2030-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME)
Acronym
CoPRIME
Condition
Acute Ischemic Stroke
Intervention (Drug)
Aspirin + Clopidogrel
Intervention (Drug)
Aspirin
Intervention (Drug)
Aspirin + Ticagrelor
Lead sponsor
University of Alberta (class: other)
Collaborator
University of Calgary (class: other)

Record details

Record id
cardio:ct-nct07844603
Content hash
a8740235fefead5522fec6896006e533055b8608207560ba0b89f29d5bc6f489